Skip to main content
Eli LillyAcquisition

Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis

Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.

What happened

Eli Lilly and Company has entered into a definitive agreement to acquire Calytrix Bio for up to $1.5 billion in cash.

Source

Article excerpt

Calytrix Bio's potentially best-in-class preclinical program is a novel biparatopic antibody designed to deliver pan-mutant calreticulin activity Acquisition broadens Lilly's presence in the myeloproliferative neoplasm field and builds on Lilly's established capabilities in blood cancers WELLESLEY, Mass., Nov. 16, 2026 /PRNewswire/ -- Calytrix Bio, Inc. ("Calytrix"), a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Eli Lilly and Company ("Lilly") to acquire Calytrix. Calytrix's lead asset is an investigational biparatopic antibody for mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). It is designed to deliver disease-modifying pan-mutant activity, with a safety and convenience profile that supports early intervention and long-term treatment. Current drug therapies for ET and MF primarily manage symptoms and complications, creating an opportunity for precision therapies that target the disease driver mutations. Mutant CALR provides a tumor-specific cell-surface target with the potential to deplete the disease-driving mutant clone while sparing normal tissues and preserving healthy hematopoiesis. "Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad...

Keep reading with a free account

The rest of this article, and every signal for Eli Lilly, is in your free account.

Extracted from this sentence

Under the terms of the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.

Extracted by Autobound

From the Signal API record
Event
Acquisition

What this signalsIntegration work after a deal often opens needs for new systems and services.

Amount
$1.5B
Location
Wellesley Hills, Massachusetts, United States

Companies

  • Calytrix Bio, Inc.Targetcalytrixbio.com

More acquisition signals at other companies

The full record

From the Signal API record

Numbers

Amount (USD)
$1.5B

Extraction

Confidence
95%
Detected
Nov 16, 2026
signal_type
news
signal_subtype
acquires

Use this data

Get every acquisition signal for Eli Lilly and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”

  2. Send it to your own tools

    The Signal API returns acquisition signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/8d17236c-57e8-9b73-e354-b6e890507e45 returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "8d17236c-57e8-9b73-e354-b6e890507e45",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-11-16T11:45:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/calytrix-bio-enters-an-agreement-to-be-acquired-by-lilly-to-advance-outcomes-for-patients-living-with-essential-thrombocythemia-and-myelofibrosis-302940325.html",
    "title": "Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis",
    "excerpt": "Calytrix Bio's potentially best-in-class preclinical program is a novel biparatopic antibody designed to deliver pan-mutant calreticulin activity Acquisition broadens Lilly's presence in the myeloproliferative neoplasm field and builds on Lilly's established capabilities in blood cancers WELLESLEY, Mass. , Nov. 16, 2026 /PRNewswire/ -- Calytrix Bio, Inc. (\"Calytrix\"), a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Eli Lilly and Company (\"Lilly\") to acquire Calytrix. Calytrix's lead asset is an investigational biparatopic antibody for mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). It is designed to deliver disease-modifying pan-mutant activity, with a safety and convenience profile that supports early intervention and long-term treatment. Current drug therapies for ET and MF primarily manage symptoms and complications, creating an opportunity for precision therapies that target the disease driver mutations. Mutant CALR provides a tumor-specific cell-surface target with the potential to deplete the disease-driving mutant clone while sparing normal tissues and preserving healthy hematopoiesis. \"Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms,\" said Brad...",
    "summary": "Eli Lilly and Company has entered into a definitive agreement to acquire Calytrix Bio for up to $1.5 billion in cash.",
    "location": "Wellesley Hills, Massachusetts, United States",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS2035148/Calytrix-Bio-Logo.jpg?id=OA3079125&p=facebook",
    "confidence": 0.95,
    "published_at": "2026-11-16T11:45:00Z",
    "location_data": [
      {
        "city": "Wellesley Hills",
        "state": "Massachusetts",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Under the terms of the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.",
    "amount_normalized": 1500000000,
    "related_company_name": "Calytrix Bio, Inc.",
    "related_company_domain": "calytrixbio.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.